Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease Oct 5, 2016
DelMar Pharmaceuticals Presents Data Supporting the Potential of VAL-083 as a New Treatment for Ovarian Cancer at the 11th Biennial Ovarian Cancer Research Symposium Sep 14, 2016
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer Sep 8, 2016
DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016 Aug 31, 2016
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy Aug 30, 2016
DelMar Pharmaceuticals to Present at the 11th Biennial Ovarian Cancer Research Symposium Aug 12, 2016
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208) Aug 12, 2016
RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis Aug 2, 2016
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs Jul 22, 2016
RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection Jul 22, 2016
RedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016 Jul 20, 2016
RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment Jul 14, 2016
RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT™ for Migraines with Grupo JUSTE in Spain and Additional Potential Territories Jul 6, 2016
RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn’s Disease Associated with MAP Infection Jun 23, 2016
RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors Jun 22, 2016
